Published in Int J Oncol on March 30, 2011
Autophagy-related gene 12 (ATG12) is a novel determinant of primary resistance to HER2-targeted therapies: utility of transcriptome analysis of the autophagy interactome to guide breast cancer treatment. Oncotarget (2012) 1.14
Xenohormetic and anti-aging activity of secoiridoid polyphenols present in extra virgin olive oil: a new family of gerosuppressant agents. Cell Cycle (2013) 1.00
Adaptive cellular stress pathways as therapeutic targets of dietary phytochemicals: focus on the nervous system. Pharmacol Rev (2014) 0.87
Sulforaphane induced cell cycle arrest in the G2/M phase via the blockade of cyclin B1/CDC2 in human ovarian cancer cells. J Ovarian Res (2013) 0.86
Effect of rosemary polyphenols on human colon cancer cells: transcriptomic profiling and functional enrichment analysis. Genes Nutr (2012) 0.85
Phenolic secoiridoids in extra virgin olive oil impede fibrogenic and oncogenic epithelial-to-mesenchymal transition: extra virgin olive oil as a source of novel antiaging phytochemicals. Rejuvenation Res (2012) 0.84
Damage of neuroblastoma cell SH-SY5Y mediated by MPP+ inhibits proliferation of T-cell leukemia Jurkat by co-culture system. Int J Mol Sci (2014) 0.79
Assessment of the antioxidant activity of an olive oil total polyphenolic fraction and hydroxytyrosol from a Greek Olea europea variety in endothelial cells and myoblasts. Int J Mol Med (2017) 0.75
Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy (2012) 20.08
The active form of the metabolic sensor: AMP-activated protein kinase (AMPK) directly binds the mitotic apparatus and travels from centrosomes to the spindle midzone during mitosis and cytokinesis. Cell Cycle (2009) 2.03
Metformin: multi-faceted protection against cancer. Oncotarget (2011) 2.00
Functional and structural markers of atherosclerosis in human immunodeficiency virus-infected patients. J Am Coll Cardiol (2006) 1.99
Dynamic emergence of the mesenchymal CD44(pos)CD24(neg/low) phenotype in HER2-gene amplified breast cancer cells with de novo resistance to trastuzumab (Herceptin). Biochem Biophys Res Commun (2010) 1.91
Autophagy facilitates the development of breast cancer resistance to the anti-HER2 monoclonal antibody trastuzumab. PLoS One (2009) 1.91
The antidiabetic drug metformin suppresses HER2 (erbB-2) oncoprotein overexpression via inhibition of the mTOR effector p70S6K1 in human breast carcinoma cells. Cell Cycle (2009) 1.89
Immunohistochemical analysis of paraoxonases-1, 2, and 3 expression in normal mouse tissues. Free Radic Biol Med (2008) 1.86
Metformin and cancer: doses, mechanisms and the dandelion and hormetic phenomena. Cell Cycle (2010) 1.85
Metformin regulates breast cancer stem cell ontogeny by transcriptional regulation of the epithelial-mesenchymal transition (EMT) status. Cell Cycle (2010) 1.78
New variants in the mitochondrial genomes of schizophrenic patients. Eur J Hum Genet (2006) 1.72
The anti-diabetic drug metformin suppresses self-renewal and proliferation of trastuzumab-resistant tumor-initiating breast cancer stem cells. Breast Cancer Res Treat (2010) 1.71
Solid neuroendocrine breast carcinomas: incidence, clinico-pathological features and immunohistochemical profiling. Oncol Rep (2008) 1.67
Genome-wide inhibitory impact of the AMPK activator metformin on [kinesins, tubulins, histones, auroras and polo-like kinases] M-phase cell cycle genes in human breast cancer cells. Cell Cycle (2009) 1.66
Membrane-related effects underlying the biological activity of the anthraquinones emodin and barbaloin. Biochem Pharmacol (2004) 1.64
Metformin-induced preferential killing of breast cancer initiating CD44+CD24-/low cells is sufficient to overcome primary resistance to trastuzumab in HER2+ human breast cancer xenografts. Oncotarget (2012) 1.61
Metformin against TGFβ-induced epithelial-to-mesenchymal transition (EMT): from cancer stem cells to aging-associated fibrosis. Cell Cycle (2010) 1.60
Pharmacological inhibitors of Fatty Acid Synthase (FASN)--catalyzed endogenous fatty acid biogenesis: a new family of anti-cancer agents? Curr Pharm Biotechnol (2006) 1.58
The paraoxonases: role in human diseases and methodological difficulties in measurement. Crit Rev Clin Lab Sci (2009) 1.57
Plasma homocysteine concentrations in patients with liver cirrhosis. Clin Chem (2002) 1.50
Dilated aortic root is related to a global aortic dilating diathesis. J Vasc Surg (2010) 1.48
The relationship between the antioxidant and the antibacterial properties of galloylated catechins and the structure of phospholipid model membranes. Free Radic Biol Med (2003) 1.44
Autophagy in stem cells. Autophagy (2013) 1.43
Heterozygous apolipoprotein (a) status and protein expression as a risk factor for premature coronary heart disease. J Lab Clin Med (2002) 1.40
Metformin is synthetically lethal with glucose withdrawal in cancer cells. Cell Cycle (2012) 1.39
[Clinical applications of erythropoietin: Impact on blood transfusion]. Med Clin (Barc) (2002) 1.39
Atherosclerosis in patients infected with HIV is influenced by a mutant monocyte chemoattractant protein-1 allele. Circulation (2004) 1.37
mTOR-regulated senescence and autophagy during reprogramming of somatic cells to pluripotency: a roadmap from energy metabolism to stem cell renewal and aging. Cell Cycle (2011) 1.32
Metabolomic fingerprint reveals that metformin impairs one-carbon metabolism in a manner similar to the antifolate class of chemotherapy drugs. Aging (Albany NY) (2012) 1.31
Phenolic molecules in virgin olive oils: a survey of their sensory properties, health effects, antioxidant activity and analytical methods. An overview of the last decade. Molecules (2007) 1.25
AMPK: Evidence for an energy-sensing cytokinetic tumor suppressor. Cell Cycle (2009) 1.23
The Warburg effect version 2.0: metabolic reprogramming of cancer stem cells. Cell Cycle (2013) 1.20
Mitochondrial fusion by pharmacological manipulation impedes somatic cell reprogramming to pluripotency: new insight into the role of mitophagy in cell stemness. Aging (Albany NY) (2012) 1.20
Fatty acid synthase: association with insulin resistance, type 2 diabetes, and cancer. Clin Chem (2009) 1.20
Comparison of rosiglitazone and metformin for treating HIV lipodystrophy: a randomized trial. Ann Intern Med (2005) 1.19
Feeding apolipoprotein E-knockout mice with cholesterol and fat enriched diets may be a model of non-alcoholic steatohepatitis. Mol Cell Biochem (2005) 1.19
Autophagy positively regulates the CD44(+) CD24(-/low) breast cancer stem-like phenotype. Cell Cycle (2011) 1.19
Epithelial-to-mesenchymal transition (EMT) confers primary resistance to trastuzumab (Herceptin). Cell Cycle (2012) 1.18
CCL2 shapes macrophage polarization by GM-CSF and M-CSF: identification of CCL2/CCR2-dependent gene expression profile. J Immunol (2014) 1.18
Targeting fatty acid synthase in breast and endometrial cancer: An alternative to selective estrogen receptor modulators? Endocrinology (2006) 1.17
Regulation of serum paraoxonase activity by genetic, nutritional, and lifestyle factors in the general population. Clin Chem (2003) 1.16
Metabolomic assessment of the effect of dietary cholesterol in the progressive development of fatty liver disease. J Proteome Res (2010) 1.15
An update of the mechanisms of resistance to EGFR-tyrosine kinase inhibitors in breast cancer: Gefitinib (Iressa) -induced changes in the expression and nucleo-cytoplasmic trafficking of HER-ligands (Review). Int J Mol Med (2007) 1.14
Autophagy-related gene 12 (ATG12) is a novel determinant of primary resistance to HER2-targeted therapies: utility of transcriptome analysis of the autophagy interactome to guide breast cancer treatment. Oncotarget (2012) 1.14
Activation of AMP-activated protein kinase (AMPK) provides a metabolic barrier to reprogramming somatic cells into stem cells. Cell Cycle (2012) 1.14
Pathway-focused proteomic signatures in HER2-overexpressing breast cancer with a basal-like phenotype: new insights into de novo resistance to trastuzumab (Herceptin). Int J Oncol (2010) 1.14
The anti-malarial chloroquine overcomes primary resistance and restores sensitivity to trastuzumab in HER2-positive breast cancer. Sci Rep (2013) 1.14
Serum paraoxonase activity: a new additional test for the improved evaluation of chronic liver damage. Clin Chem (2002) 1.13
Newly identified apolipoprotein AV gene predisposes to high plasma triglycerides in familial combined hyperlipidemia. Clin Chem (2002) 1.11
Metformin limits the tumourigenicity of iPS cells without affecting their pluripotency. Sci Rep (2012) 1.11
Insulin resistance, inflammation, and obesity: role of monocyte chemoattractant protein-1 (or CCL2) in the regulation of metabolism. Mediators Inflamm (2010) 1.09
Polo-like kinase 1 regulates activation of AMP-activated protein kinase (AMPK) at the mitotic apparatus. Cell Cycle (2011) 1.09
AMPK-sensed cellular energy state regulates the release of extracellular Fatty Acid Synthase. Biochem Biophys Res Commun (2008) 1.08
BRCA1 and acetyl-CoA carboxylase: the metabolic syndrome of breast cancer. Mol Carcinog (2008) 1.08
Nuclear reprogramming of luminal-like breast cancer cells generates Sox2-overexpressing cancer stem-like cellular states harboring transcriptional activation of the mTOR pathway. Cell Cycle (2013) 1.08
Gerosuppressant metformin: less is more. Aging (Albany NY) (2011) 1.08
IGF-1R/epithelial-to-mesenchymal transition (EMT) crosstalk suppresses the erlotinib-sensitizing effect of EGFR exon 19 deletion mutations. Sci Rep (2013) 1.07